Analysts’ Recent Ratings Updates for Ultragenyx Pharmaceutical (RARE)

Ultragenyx Pharmaceutical (NASDAQ: RARE) recently received a number of ratings updates from brokerages and research firms:

• 5/11/2026 – Ultragenyx Pharmaceutical was downgraded by Wall Street Zen from “hold” to “strong sell”.
• 5/8/2026 – Ultragenyx Pharmaceutical was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 5/8/2026 – Ultragenyx Pharmaceutical had its price target lowered by Guggenheim from $52.00 to $43.00. They now have a “buy” rating on the stock.
• 5/6/2026 – Ultragenyx Pharmaceutical had its price target raised by Wells Fargo & Company from $45.00 to $47.00. They now have an “overweight” rating on the stock.
• 5/6/2026 – Ultragenyx Pharmaceutical had its price target lowered by Wedbush from $27.00 to $26.00. They now have a “neutral” rating on the stock.
• 5/3/2026 – Ultragenyx Pharmaceutical was upgraded by Wall Street Zen from “sell” to “hold”.
• 4/29/2026 – Ultragenyx Pharmaceutical had its price target lowered by Barclays PLC from $44.00 to $43.00. They now have an “overweight” rating on the stock.
• 4/25/2026 – Ultragenyx Pharmaceutical was downgraded by Wall Street Zen from “hold” to “sell”.
• 4/24/2026 – Ultragenyx Pharmaceutical was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 4/16/2026 – Ultragenyx Pharmaceutical had its price target raised by Morgan Stanley from $50.00 to $67.00. They now have an “overweight” rating on the stock.
• 3/25/2026 – Ultragenyx Pharmaceutical was upgraded by Truist Financial Corporation to “strong-buy”.
• 3/24/2026 – Ultragenyx Pharmaceutical was downgraded by The Goldman Sachs Group, Inc. from “buy” to “neutral”. They now have a $25.00 price target on the stock, down from $61.00.

Insiders Place Their Bets

In other news, EVP Karah Herdman Parschauer sold 8,135 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $22.80, for a total value of $185,478.00. Following the completion of the sale, the executive vice president owned 76,346 shares in the company, valued at approximately $1,740,688.80. The trade was a 9.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Howard Horn sold 4,683 shares of the business’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $24.90, for a total transaction of $116,606.70. Following the completion of the sale, the chief financial officer owned 110,342 shares of the company’s stock, valued at approximately $2,747,515.80. This represents a 4.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 111,522 shares of company stock worth $2,543,214. 5.20% of the stock is owned by corporate insiders.

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.